Citi lowered the firm’s price target on Ardelyx to $13 from $14 and keeps a Buy rating on the shares. The analyst updated biotechnology models to reflect reported Q4 and 2023 financials.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx call volume above normal and directionally bullish
- Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
- Ardelyx initiated with an Outperform at Leerink
- Ardelyx, Inc. Reports Employment Inducement Grants
- Ardelyx appoints Mike Kelliher as EVP, corporate development, strategy
